Royalty Pharma plc - Ordinary Shares - Class A Aktie News

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee.

Royalty Pharma plc (NASDAQ:RPRX ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 2:50 PM EDT Company Participants Marshall Urist - Executive Vice President of Research & Investments Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.

Royalty Pharma remains a Buy supported by strong execution and upward guidance revision. RPRX trades at a significant valuation discount to biopharma peers, with 86% of its portfolio in approved therapies and robust free cash flow growth. Management projects 11–14% portfolio receipts CAGR through 2030, exceeding consensus, and demonstrates disciplined capital allocation with M&A capability.

Royalty Pharma plc (NASDAQ:RPRX ) Investor Day 2025 Conference September 11, 2025 8:30 AM EDT Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman of the Board & CEO Ashwin Pai - Executive Vice President of Investments Christopher Hite - Vice Chairman & Executive VP Brienne Kugler - Senior VP of Research & Investments...

On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform value Investments since 2020 on track to deliver mid-teens unlevered IRR, ahead of target Achieved 15% Return on Inves...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma royalties. The full report is av...

Royalty Pharma plc (NASDAQ:RPRX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Pablo Legorreta - Founder, Chairman of the Board & CEO Terrance Coyne - Executive VP & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.